Handelsbanken Fonder AB Has $139.42 Million Holdings in Edwards Lifesciences Corporation $EW

Handelsbanken Fonder AB raised its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 22.0% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,541,212 shares of the medical research company’s stock after buying an additional 278,208 shares during the period. Handelsbanken Fonder AB owned about 0.27% of Edwards Lifesciences worth $139,418,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. JPL Wealth Management LLC acquired a new position in shares of Edwards Lifesciences in the third quarter valued at $25,000. Hanson & Doremus Investment Management acquired a new stake in shares of Edwards Lifesciences during the 1st quarter worth about $25,000. MV Capital Management Inc. acquired a new stake in shares of Edwards Lifesciences during the 4th quarter worth about $26,000. RMG Wealth Management LLC bought a new stake in shares of Edwards Lifesciences during the 1st quarter worth about $26,000. Finally, Kemnay Advisory Services Inc. bought a new stake in shares of Edwards Lifesciences during the 4th quarter worth about $27,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Edwards Lifesciences Price Performance

Edwards Lifesciences stock opened at $92.01 on Tuesday. The stock’s fifty day moving average price is $88.26 and its two-hundred day moving average price is $84.14. Edwards Lifesciences Corporation has a one year low of $72.30 and a one year high of $96.29. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.52 and a quick ratio of 3.77. The firm has a market cap of $52.98 billion, a PE ratio of 52.88, a price-to-earnings-growth ratio of 2.25 and a beta of 0.85.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.04. The firm had revenue of $1.74 billion during the quarter, compared to analysts’ expectations of $1.70 billion. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The company’s quarterly revenue was up 13.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, research analysts expect that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Insider Buying and Selling

In other news, VP Donald E. Bobo, Jr. sold 23,145 shares of the business’s stock in a transaction that occurred on Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total value of $2,000,190.90. Following the completion of the transaction, the vice president directly owned 98,611 shares in the company, valued at approximately $8,521,962.62. The trade was a 19.01% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Daniel J. Lippis sold 619 shares of the company’s stock in a transaction that occurred on Friday, July 10th. The stock was sold at an average price of $91.70, for a total transaction of $56,762.30. Following the sale, the vice president directly owned 40,034 shares of the company’s stock, valued at approximately $3,671,117.80. This trade represents a 1.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 43,539 shares of company stock valued at $3,685,364 over the last quarter. 0.31% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research analysts have weighed in on the stock. Evercore reissued an “outperform” rating and issued a $100.00 price target on shares of Edwards Lifesciences in a report on Monday, July 6th. Weiss Ratings restated a “hold (c)” rating on shares of Edwards Lifesciences in a report on Friday, July 17th. Robert W. Baird upped their target price on Edwards Lifesciences from $85.00 to $87.00 and gave the company a “neutral” rating in a research report on Friday, April 24th. UBS Group assumed coverage on Edwards Lifesciences in a research note on Tuesday, July 28th. They set a “buy” rating and a $110.00 target price on the stock. Finally, Canaccord Genuity Group set a $85.00 price target on Edwards Lifesciences and gave the stock a “hold” rating in a report on Friday, April 24th. Seventeen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, Edwards Lifesciences presently has an average rating of “Moderate Buy” and a consensus price target of $100.27.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.